IP Library Patent Application 11960427
Patent Application
App. No. 11/960,427

CONJUGATE OF NATRIURETIC PEPTIDE AND ANTIBODY CONSTANT REGION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/960,427
Abstract

The present application describes a conjugate between a natriuretic peptide, such as urodilatin, and the constant region of an immunoglobulin or a fragment thereof. Also described are compositions comprising the conjugate and methods for using the conjugate.

Claims (25)

1 . A conjugate comprising a natriuretic peptide and an antibody constant region, wherein the conjugate binds to a natriuretic peptide receptor.

2 . The conjugate of claim 1 , wherein the natriuretic peptide is urodilatin.

3 . The conjugate of claim 1 , wherein the natriuretic peptide receptor is NPR-A.

4 . The conjugate of claim 1 , wherein the natriuretic peptide and the antibody constant region is linked via a linker.

5 . The conjugate of claim 1 , which is a fusion polypeptide.

6 . The conjugate of claim 5 , wherein the fusion polypeptide further comprises a peptide linker.

7 . The conjugate of claim 5 , wherein the fusion polypeptide comprises the amino acid sequence of SEQ ID NO:6 or 12.

8 . The conjugate of claim 1 , wherein the antibody constant region is linked to the N-terminus of the natriuretic peptide.

9 . The conjugate of claim 1 , wherein the antibody constant region is linked to the C-terminus of the natriuretic peptide.

10 . The conjugate of claim 1 , wherein the natriuretic peptide is linked to an internal amino acid of the antibody constant region.

11 . The conjugate of claim 1 , which activates a natriuretic peptide receptor.

12 . The conjugate of claim 1 , which has a longer serum half-life compared with the natriuretic peptide.

13 . An isolated nucleic acid comprising a polynucleotide sequence encoding a fusion polypeptide that comprises a natriuretic peptide and an antibody constant region.

14 . The nucleic acid of claim 13 , wherein the fusion polypeptide further comprises a peptide linker.

15 . The nucleic acid of claim 13 , wherein the natriuretic peptide is urodilatin.

16 . The nucleic acid of claim 13 , which comprises the polynucleotide sequence of SEQ ID NO:5 or 11.

17 . An expression cassette comprising the nucleic acid of claim 13 .

18 . An isolated host cell transfected with the expression cassette of claim 17 .

19 . The host cell of claim 18 , which is a eukaryotic cell.

20 . A method for recombinantly producing a fusion polypeptide comprising a natriuretic peptide and an antibody constant region, comprising the steps of:

a. transfecting a host cell with the expression cassette of claim 17 ; and

b. culturing the cell under the condition that are suitable for the cell to express the fusion polypeptide.

21 . The method of claim 20 , wherein the natriuretic peptide is urodilatin.

22 . A composition comprising the conjugate of claim 1 and a pharmaceutically acceptable carrier.

23 . A method for treating bacterial infection, pulmonary and bronchial diseases, renal failure, or heart failure, comprising the step of administering to a patient in need thereof an effective amount of the conjugate of claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2011
From: EKR THERAPEUTICS, INC.
To: CARDIOPEP PHARMA GMBH
Reel/Frame 026036/0786 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2008
From: PDL BIOPHARMA, INC.
To: EKR THERAPEUTICS, INC.
Reel/Frame 021843/0100 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2008
From: BHASKAR, VINAY; DUBRIDGE, ROBERT BRYAN; RAMAKRISHNAN, VANITHA; JANTZEN, HANS-MICHAEL
To: PDL BIOPHARMA, INC.
Reel/Frame 020725/0324 →